Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In Reply We thank McKenzie and Mierzwa for pointing to the article by Furdova et al,1 who also evaluated linear accelerator–based stereotactic radiosurgery (SRS) of uveal melanoma (UM). We had not seen their March-April 2012 issue when our manuscript was submitted in April 2012. Furdova et al treated 39 patients between 2001 and 2008 and our study included 78 patients between 2003 and 2008, indicating that experiences with SRS were collected during a comparable treatment period.1,2 Our treatment approach was not based on the experiences of Furdova et al, and we compared SRS as monotherapy vs planned combined SRS and tumor resection. Nonetheless, we apologize for the failure of not considering their results and certainly would like to comment on their work on SRS of UM.
Suesskind D, Paulsen F. Regarding Stereotactic Radiosurgery for Uveal Melanoma—Reply. JAMA Ophthalmol. 2014;132(3):368. doi:10.1001/jamaophthalmol.2013.5760